Inhalation Capsules Market Size and Share, by Type (Gelatin Capsules, Hypromellose Capsules); Application (Asthma Treatment, COPD Management and Others) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• A major help in treating COPD, asthma, and respiratory disorders: The increasing prevalence of asthma and Chronic obstructive pulmonary disease (COPD) leads to an upsurge in demand for efficient and accurate respiratory care. Moreover, healthcare professionals, especially those who are established/involved in the asthma and COPD drugs are inclined to adopt inhalation capsules for the administration of the drugs directly to the respiratory tract of the patients. This helps the patients who receive the proper treatment and also increases the effectiveness of the drug delivery. inhalation capsules are essential for COPD treatment because the total number of deaths caused by COPD is supposed to increase by 30% over the upcoming 10 years. COPD is considered to be the third leading cause of death and will likely emerge as the fifth major cause of disability by 2020. So, medical intervention is immediately needed with the help of inhalation capsules.
• Versatility in dosage forms: The availability of doses in various forms, such as powders, liquids, and aerosols, meets the diverse needs of patients. It also increases the stability of medication and reduces deterioration when using inhalation capsules. Dry powder or aerosolized pharmaceutical substances are more protected from some unspecified environmental factors that may affect their stability. This causes the drugs to have a longer shelf life, and due to this, the number of times drugs will be replenished in the healthcare system will be less, which leads to added cost-effectiveness. From the above analysis, it can be forecasted that the following factors are expected to fuel the growth of the inhalation capsules market. According to NIH, also known as The National Institute of Health/National Library of Medicine, the dosage of the drug for the treatment of lung deposition varies among different DPIs or inhalation capsules. Approximately 12-40% of the emitted dose is delivered to the lungs, with 20–25% of the drug being retained within the device.
   
• Growing awareness in preventative healthcare and respiratory care: The growing emphasis on preventative healthcare measures around the globe, such as the effective management and diagnosis of respiratory cases, is anticipated to increase demand for dry powder inhalers. They are used in preventative care by offering targeted drug delivery to the lungs, thus reducing any exacerbations and improving overall health conditions. The government initiatives aim to improve the respiratory healthcare infrastructure by ensuring access to affordable inhalation therapies and increasing awareness about respiratory infections and diseases that are projected to increase the number of respiratory devices, including respiratory protection equipment, digital respiratory devices, etc. There is a major growing preference for non-invasive treatment options in comparison to invasive ones because they offer a precise way to administer medication to our lungs directly. Capsule-based dry powder inhalers are set to contribute almost 31.9% of the global shares of the inhalation capsules market by the end of 2036.

Challenges

• Instability of the drug within the capsule: Among the major concerns is drug stability in the inhalation capsules. Stability is a critical problem for the pharmaceutical industry when attempting to deliver certain drugs in powder form for long periods. Environmental factors such as humidity, temperature, and light can also alter medication stability, thus reducing their efficiency. The stability of the products in inhalation capsules poses one of the most critical issues for pharmaceutical companies that aim to preserve the therapeutic value of the drugs after packaging. A drawback associated with inhalation capsules is the contamination risk.
• Inhalation of pollutants: Any pollution might be risky for health if inhaled; it is, therefore, a significant threat to patient safety. This risk is well managed; however, by maintaining high standards of manufacturing procedures, contamination is still a factor that must constantly be checked and controlled. Inhalation capsules could also pose problems related to dose control. This method represents a challenge when it comes to dosing, especially with powdered drugs as opposed to liquid solutions.